Talk:Neonatal fragment crystallizable receptor

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).
	This article is within the scope of the Cell Signaling task force, a task force which is currently considered to be inactive.

Untitled[edit]

I am a Carleton College student currently in an Immunology course. I plan on adding information to this page from the following sources:

Kuo, Timothy T., Kristi Baker, Masaru Yoshida, Shuo-Wang Qiao, Victoria G. Aveson, Wayne I. Lencer, and Richard S. Blumberg. 2010. Neonatal Fc receptor: from immunity to therapeutics. Journal of Clinical Immunology 30(6): 777-789.
Roopenian, Derry C.; Akilesh, Shreeram (2007-09-01). "FcRn: the neonatal Fc receptor comes of age". Nature Reviews Immunology 7 (9): 715–725. doi:10.1038/nri2155. ISSN 1474-1733.
Kuo, Timothy T; Aveson, Victoria G (2011-01-01). "Neonatal Fc receptor and IgG-based therapeutics". mAbs 3 (5): 422–430. doi:10.4161/mabs.3.5.16983. ISSN 1942-0862. PMC 3225846. PMID 22048693.
Sockolosky, Jonathan T.; Szoka, Francis C. (2015-08-30). "The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy". Advanced Drug Delivery Reviews. Editor's Collection 2015 91: 109–124. doi:10.1016/j.addr.2015.02.005. PMC 4544678. PMID 25703189.
Andersen, Jan Terje; Dalhus, Bjørn; Cameron, Jason; Daba, Muluneh Bekele; Plumridge, Andrew; Evans, Leslie; Brennan, Stephan O.; Gunnarsen, Kristin Støen; Bjørås, Magnar (2012-01-03). "Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor". Nature Communications 3: 610. doi:10.1038/ncomms1607. ISSN 2041-1723. PMC 3272563. PMID 22215085.

Immcarle10 (talk) 05:06, 3 February 2016 (UTC)[reply]

I would like to add the following information into the appropriate spots in the article. I did end up changing some of my sources from the previously posted bibliography to have more current reviews.

Other immunotherapies aim to prevent inflammation by blocking autoantibody binding to FcRn with higher affinity antibodies.[1]

In the kidneys, FcRn is expressed on epithelial cells called podocytes to prevent IgG from clogging the glomeruli and albumin from being excreted.[2]

Current studies are investigating FcRn in the liver because there is relatively low concentrations of both IgG and albumin in liver bile despite high concentrations in the blood.[3]

Neonatal Fc receptor expression is up-regulated by proinflammatory cytokine, TNF-α, and down-regulated by IFN-γ.[4]

FcRn is expressed on antigen-presenting lymphocytes like dendritic cells and is also expressed in neutrophils to help clear opsonized bacteria.[4]

Several autoimmune disorders are caused by the reaction of IgG to self antigens. New therapies seek to disrupt the IgG-FcRn interaction to increase the clearance of these pathogenic IgG from the body. One such therapy is the infusion of intravenous immunoglobulin (IVIg) to bind available FcRn and prevent pathogenic IgG binding, thereby increasing pathogenic IgG clearance.[5]

I would like to add an image on FcRn-mediated recycling/transcytosis from the cited source, but sharing images on Wikipedia seems like a lot of trouble. I may just make my own image.[5]

[1] Nimmerjahn, Falk; Ravetch, Jeffrey V. (2008-01-01). "Anti-Inflammatory Actions of Intravenous Immunoglobulin". Annual Review of Immunology 26 (1): 513–533. doi:10.1146/annurev.immunol.26.021607.090232. PMID 18370923.

[2] Bern, Malin; Sand, Kine Marita Knudsen; Nilsen, Jeannette; Sandlie, Inger; Andersen, Jan Terje (2015-08-10). "The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery". Journal of Controlled Release 211: 144–162. doi:10.1016/j.jconrel.2015.06.006.

[3] Sand, Kine Marita Knudsen; Bern, Malin; Nilsen, Jeannette; Noordzij, Hanna Theodora; Sandlie, Inger; Andersen, Jan Terje (2015-01-26). "Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics". Frontiers in Immunology 5. doi:10.3389/fimmu.2014.00682. ISSN 1664-3224. PMC 4306297. PMID 25674083.

[4] Kuo, Timothy T., Kristi Baker, Masaru Yoshida, Shuo-Wang Qiao, Victoria G. Aveson, Wayne I. Lencer, and Richard S. Blumberg. 2010. Neonatal Fc receptor: from immunity to therapeutics. Journal of Clinical Immunology 30(6): 777-789.

[5] Sockolosky, Jonathan T.; Szoka, Francis C. (2015-08-30). "The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy". Advanced Drug Delivery Reviews. Editor's Collection 2015 91: 109–124. doi:10.1016/j.addr.2015.02.005. PMC 4544678. PMID 25703189. — Preceding unsigned comment added by Immcarle10 (talk • contribs) 04:44, 10 February 2016 (UTC)[reply]